Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marnix H Geukes Foppen"'
Autor:
Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated
Externí odkaz:
https://doaj.org/article/dcfa2791fafa4572a3dce6276ee8be68
Autor:
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Publikováno v:
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485a
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292
Autor:
Valesca P. Retèl, Lotte M. G. Steuten, Marnix H. Geukes Foppen, Janne C. Mewes, Melanie A. Lindenberg, John B. A. G. Haanen, Wim H. van Harten
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized
Externí odkaz:
https://doaj.org/article/e50a67f8eb514c8f865b0a96c13e2530
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a56245b818de085dbed173af7f8d70c
https://doi.org/10.1097/cmr.0000000000000429
https://doi.org/10.1097/cmr.0000000000000429
Autor:
Daniel S. Peeper, Christian U. Blank, Hans W.M. Niessen, Julia Boshuizen, Thomas Kuilman, Aida Shahrabi, Ji Ying Song, Xiangjun Kong, Kristel Kemper, Marnix H Geukes Foppen, Elisa A. Rozeman
Publikováno v:
Nature, 550(7675), 270-274. Nature Publishing Group
Nature
Kong, X, Kuilman, T, Shahrabi, A, Boshuizen, J, Kemper, K, Song, J Y, Niessen, H W M, Rozeman, E A, Foppen, M H G, Blank, C U & Peeper, D S 2017, ' Cancer drug addiction is relayed by an ERK2-dependent phenotype switch ', Nature, vol. 550, no. 7675, pp. 270-274 . https://doi.org/10.1038/nature24037
Nature
Kong, X, Kuilman, T, Shahrabi, A, Boshuizen, J, Kemper, K, Song, J Y, Niessen, H W M, Rozeman, E A, Foppen, M H G, Blank, C U & Peeper, D S 2017, ' Cancer drug addiction is relayed by an ERK2-dependent phenotype switch ', Nature, vol. 550, no. 7675, pp. 270-274 . https://doi.org/10.1038/nature24037
Observations from cultured cells 1-3, animal models4 and patients5-7raise the possibility that the dependency of tumours on the therapeutic drugs to which they have acquired resistance represents a vulnerability with potential applications in cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df46b5ac7614ee892024f1d1e15da0ca
https://doi.org/10.1038/nature24037
https://doi.org/10.1038/nature24037
Autor:
Christian U. Blank, Michele Maio, Michael A. Postow, Benjamin Weide, Phillip Wong, Dirk Schadendorf, Anna Maria Di Giacomo, Florian Heubach, Jianda Yuan, Paolo A. Ascierto, Amir Khammari, Marnix H Geukes Foppen, Brigitte Dréno, Graham Pawelec, Claus Garbe, Emanuela Romano, Domenico Mallardo, Bastian Schilling, Jedd D. Wolchok, Kilian Wistuba-Hamprecht, Alexander Martens
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. 〈10.1016/j.ejca.2016.12.011〉
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
European Journal of Cancer, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. 〈10.1016/j.ejca.2016.12.011〉
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
International audience; The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a6982f18635313131b596d20ee2f8d
https://doi.org/10.1016/j.ejca.2016.12.011
https://doi.org/10.1016/j.ejca.2016.12.011
Publikováno v:
Journal of Cancer Research and Therapeutics. 16:170
With the discovery of v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, new treatment possibilities arose against metastatic melanoma. A frequent adverse effect of BRAF inhibitor therapy is the induction of epithelial proliferations su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ca332f1d792273b95fd41a0eec86d1c
https://doi.org/10.4103/jcrt.jcrt_317_17
https://doi.org/10.4103/jcrt.jcrt_317_17
Autor:
Melanie Lindenberg, Wim H. van Harten, Valesca P. Retèl, John B. A. G. Haanen, Joost H. van den Berg, Marnix H Geukes Foppen
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Journal of Immunotherapy, 41(9), 413-425. Lippincott Williams and Wilkins
Journal of Immunotherapy, 41(9), 413-425. Lippincott Williams and Wilkins
Supplemental Digital Content is available in the text.
Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a Euro
Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a Euro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4a7b685f125c616ec3d01d4749c6b1
https://pubmed.ncbi.nlm.nih.gov/30300260
https://pubmed.ncbi.nlm.nih.gov/30300260
Autor:
Wim H. van Harten, Janne C. Mewes, Marnix H Geukes Foppen, Lotte Maria Gertruda Steuten, Valesca P. Retèl, John B. A. G. Haanen, Melanie Lindenberg
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
BMC cancer, 18(1):895. BioMed Central
BMC cancer, 18(1):895. BioMed Central
Background An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e1c975559dbbf7e956f2fb5704ff458
https://doi.org/10.1186/s12885-018-4788-5
https://doi.org/10.1186/s12885-018-4788-5
Autor:
David W. Vredevoogd, David Satijn, Marnix H Geukes Foppen, Elisa A. Rozeman, Aida Shahrabi, Jens Thing Mortensen, Thomas Kuilman, Julia Boshuizen, Christian U. Blank, Elke Gresnigt-van den Heuvel, Nora Pencheva, Oscar Krijgsman, Daniel S. Peeper, Louise A. Koopman, Esther C.W. Breij, Paul W. H. I. Parren, Kristel Kemper, Ji-Ying Song, Maarten L. Janmaat, Maarten A. Ligtenberg
Publikováno v:
Nature Medicine, 24(2), 203
Intratumor heterogeneity is a key factor contributing to therapeutic failure and, hence, cancer lethality. Heterogeneous tumors show partial therapy responses, allowing for the emergence of drug-resistant clones that often express high levels of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff1dd468b21966ffd7a2decddea84f3
https://hdl.handle.net/1887/96424
https://hdl.handle.net/1887/96424
